HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Conditions
Juvenile Myelomonocytic Leukemia · Recurrent Acute Biphenotypic Leukemia · Recurrent Acute Undifferentiated Leukemia · Recurrent Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood Acute Myeloid Leukemia · Refractory Acute Lymphoblastic Leukemia · Refractory Adult Acute Lymphoblastic Leukemia · Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive · Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm · Recurrent Myelodysplastic Syndrome · Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm · Refractory Myelodysplastic Syndrome · Acute Undifferentiated Leukemia · Mixed Phenotype Acute Leukemia · Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive · Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive · Recurrent Acute Lymphoblastic Leukemia · Recurrent Acute Myeloid Leukemia · Myelodysplastic Syndrome · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Acute Biphenotypic Leukemia · Chronic Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Minimal Residual Disease · Recurrent Chronic Myelomonocytic Leukemia · Recurrent Mixed Phenotype Acute Leukemia · Leukemia · Chronic Myeloid Leukemia, BCR-ABL1 Positive
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Principal Investigator (Elizabeth Krakow)
Study leads
Elizabeth Krakow
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium